WebDisclosure WebDisclosure
Basculer en Français
11290 Companies
250856 Keywords
179676 Articles
136697 Press releases
Headlines Articles Press releases Vascular Therapies Remove
  1. Home
  2. Companies
  3. Vascular Therapies
WebDisclosure
Basculer en Français
Headlines Articles Press releases

News

  • BRIEF

    published on 08/05/2024 at 16:05, 2 years 3 months ago

    Vascular Therapies Completes Enrollment in Phase III ACCESS 2 Study for Sirogen

    Clinical Trial Vascular Access Sirolimus AV Fistula Hemodialysis
  • BRIEF

    published on 08/05/2024 at 16:05, 2 years 3 months ago

    Vascular Therapies achève son recrutement dans l'étude de phase III ACCESS 2 pour Sirogen

    Essai Clinique Sirolimus Accès Vasculaire Fistule AV Hémodialyse
  • PRESS RELEASE

    published on 08/05/2024 at 16:00, 2 years 3 months ago

    Vascular Therapies Completes Enrollment in the ACCESS 2 Study, a Phase III Multinational Randomized Clinical Trial of the Sirolimus Eluting Collagen Implant (Sirogen) for the Surgical Creation of Arteriovenous Fistula for Hemodialysis Vascular Access

    Vascular Therapies completes enrollment in Phase III ACCESS 2 trial to evaluate perivascular sirolimus for AV fistula in kidney disease patients. Topline results expected Q2 2025
    Kidney Disease AV Fistula Vascular Therapies Perivascular Sirolimus ACCESS 2 Trial
    Logo of Vascular Therapies
Accesswire
  • Published on 11/06/2026 at 05:15, 3 hours 37 minutes ago

    Valeo and QNX Unveil A New Smart Camera Platform at CIIE, Secures Multiple Design Wins

  • Published on 11/06/2026 at 01:20, 7 hours 32 minutes ago

    Presentation to Munich Mining Conference

  • Published on 11/06/2026 at 00:53, 7 hours 59 minutes ago

    Sekur Private Data Engages Darkstar Capital for Investor Awareness and Sekur Product Distribution

  • Published on 11/06/2026 at 00:45, 8 hours 7 minutes ago

    Gabriel Announces Closure of ICSID Annulment Proceedings

  • Published on 11/05/2026 at 23:55, 8 hours 57 minutes ago

    Santé Canada autorise deux vaccins à ARNm de Moderna : un vaccin contre la grippe et un vaccin combiné contre la grippe et la COVID-19

View all ACCESSWIRE
EQS Group
  • Published on 11/06/2026 at 08:00, 52 minutes ago

    Gledhow Investments plc: Strategic Update: Originating the Next Generation of Listed Natural Resources Companies; Issue of Equity and Repayment of all outstanding Debt

  • Published on 11/06/2026 at 08:00, 52 minutes ago

    Cairn Homes Plc: Transaction in Own Shares

  • Published on 11/06/2026 at 08:00, 52 minutes ago

    Schweizer Electronic AG continues on its growth trajectory and achieves a turnaround in earnings in the third quarter

  • Published on 11/06/2026 at 07:30, 1 hour 22 minutes ago

    Baader Bank launches Baader Trading Charity Weeks in support of BILD hilft e.V. „Ein Herz für Kinder“

  • Published on 11/06/2026 at 07:00, 1 hour 52 minutes ago

    ARYZTA announces upcoming departure of its CFO

View all EQS
Les Echos
  • Published on 11/05/2026 at 18:21, 14 hours 30 minutes ago

    Capital et droits de vote au 31 octobre 2026

  • Published on 11/05/2026 at 18:21, 14 hours 30 minutes ago

    Total number of voting rights and shares making up the share capital at October 31, 2026

  • Published on 11/05/2026 at 18:01, 14 hours 50 minutes ago

    LNA SANTE : Chiffre d'Affaires T3 2026

  • Published on 11/05/2026 at 17:50, 15 hours 2 minutes ago

    NRJ GROUP - Financial information Q3 2026

  • Published on 11/05/2026 at 17:50, 15 hours 2 minutes ago

    NRJ GROUP - Information financière T3 2026

View all LES ECHOS COMFI WIRE

With webdisclosure.com, you can follow all the latest financial news in real time from the best sources for companies listed on the Paris, Brussels, Amsterdam, Lisbon, Frankfurt and New York stock exchanges. You'll have access to summary articles written by us and press releases published by the companies themselves.

©Dissemination technology Webdisclosure.com - copyright 2026 SYMEX ECONOMICS all rights reserved

WebDisclosure

87, rue Ordener - 75018 Paris

Contact us

+33 1 42 23 83 61

Contact Authors Cookies policy Terms and conditions Privacy policy